Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Issue 95Issue 514Medical DevicesPublic Health

FDA Approves Combined Diabetes Management System

The FDA approved Medtronic's MiniMed Paradigm REAL-Time Revel System, a diabetes management system that combines an insulin pump with a glucose monitoring system. The system may represent the next step toward an artificial pancreas. 

Advertisement

"The MiniMed Paradigm Revel System can help a patient feel more secure by giving early warning of one of their greatest concerns, hypoglycemia, while continuing to simplify the complexity of diabetes management with easy-to-use features," said Katie Szyman, president of the diabetes business and senior vice president at Medtronic, in a company news release.

The system includes "smart" insulin pump therapy and continuous glucose monitoring with predictive alerts that can give early warning of impending hypoglycemia or hyperglycemia. These alerts allow people with diabetes to intervene with appropriate action to prevent dangerous high or low glucose events.

In addition, the system includes online therapy management software that helps patients with diabetes and their healthcare providers evaluate and manage treatment and make needed adjustments based on easy-to-read reports, charts, and graphs.

Trend alerts detected by the system's glucose sensors can notify patients of rapid changes in glucose levels, which they need to confirm with a fingerstick glucose measurement and then take immediate corrective or preventative action, if needed.

Predictive and rate-of-change alerts, as well as other new features, help achieve optimal glucose target range by giving earlier warnings of potential glycemic excursions. These alerts can be tailored as appropriate for a specific patient's lifestyle; for example, by creating different settings for exercise or for management of nocturnal hypoglycemia. Compared with the standard low-glucose alert, the use of predictive alerts improved detection of hypoglycemic events by 36%, based on findings from a recent Medtronic study.

Similarly, insulin delivery can be customized to specific needs because of new features in the insulin pump. Children or other patients who are sensitive to insulin can now receive insulin in smaller increments (0.025 units per hour), and insulin-resistant patients with Type 2 diabetes can more tightly control their glucose levels using the new 1:1 carbohydrate ratio. The system also allows for missed meal bolus reminders.

The Juvenile Diabetes Research Foundation International-funded studies and REAL Trend study, as well as other evidence, suggests that increased use of personal continuous glucose monitoring is associated with better average glucose control, as reflected in A1c, without increased hypoglycemic events. Nearly all US private and government insurance programs cover the costs of insulin pumps, and nearly 90% of Type 1 diabetes patients with private insurance are covered for continuous glucose monitoring costs, provided they meet medical criteria. In the United States, personal continuous glucose monitoring is approved for use by people at least 7 years of age.

"Recent clinical evidence clearly supports that insulin pump therapy combined with continuous glucose monitoring improves patients' A1c while reducing the relative risk of severe hypoglycemia," said William Tamborlane, MD, professor of pediatrics and chief of pediatric endocrinology at Yale University School of Medicine in New Haven, CT, in a company news release.

"Advances such as predictive alerts and smaller basal delivery rates can help physicians and patients customize therapy to meet individual needs. This ultimately simplifies some of the complexity of daily diabetes management," Dr. Tamborlane said.

The system is immediately available, Medtronic said.

 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 March, 2010 and appeared in  Issue 95Issue 514Medical DevicesPublic Health

Past five issues: SGLT-2 Inhibitors Special Edition July 2015 | Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
Posted July 17, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
Ancestral Diets Can Determine Vulnerability to Type 2 Diabetes
Posted July 17, 2015
Impact of Exercise in Type 2 Diabetes Patients
Posted July 23, 2015
Two Gene Mutations Identified in Increased Risk of Obesity and Diabetes
Posted July 23, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you have any patients on a dual therapy of a DPP-4 and a SGLT-2 who have reached their goal A1c?

CME/CE of the Week
Diabetic Emergencies
Dina Green, MD
Category: General Diabetes
CE Credits: 1.0